Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results

        -- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising – -- Strong Financial Results for Q2 and YTD FY 2019 -- -- Company to Host Investor Conference Call on Wednesday, May 15, 2019 , 8 a.m. ET – MIAMI , May 15, 2019 (GLOBE NEWSWIRE) -- Veru Inc.

May 15th, 2019|

Veru to Participate in Two Investor Conferences in March

MIAMI , March 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU ), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced its participation in two upcoming investor

March 12th, 2019|

Veru Reports Strong Fiscal 2019 First Quarter Financial Results

     -- Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019;  Two Prostate Cancer Clinical Trials Enrolling -- -- Company to Host Investor Conference Call on Wednesday, February 13, 2019 , 8 a.m. ET -- MIAMI , Feb. 13, 2019 (GLOBE NEWSWIRE) --   Veru Inc.

February 13th, 2019|